Andrew Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jing Li
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
17 shared publications - Seongho Kim
Department of Oncology, Wayne State University School of Medicine, Detroit, MI
10 shared publications - Charuka Wickramasinghe
Karmanos Cancer Institute Wayne State University School of Medicine Detroit Michigan USA
8 shared publications - Yuanyuan Jiang
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
8 shared publications - Xun Bao
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
7 shared publications - Artak Tovmasyan
Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Figure S1 Population mean plasma concentration – time profiles of the four model drugs following their respective standard dosing regimens (as shown in Table 1). Profiles were simulated in a typical individual (body weight of 70-kg and body surface area of 1.8 m2) using the published population pharmacokinetic parameters in cancer patients (as summarized in Table 1).
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Figure S1 Population mean plasma concentration – time profiles of the four model drugs following their respective standard dosing regimens (as shown in Table 1). Profiles were simulated in a typical individual (body weight of 70-kg and body surface area of 1.8 m2) using the published population pharmacokinetic parameters in cancer patients (as summarized in Table 1).
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose:Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design:A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results:Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions:These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose:Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design:A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results:Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions:These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S2 Drug-specific parameters
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S2 Drug-specific parameters
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S1 System-specific parameters for the 9-CNS PBPK model*
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S1 System-specific parameters for the 9-CNS PBPK model*
- 27 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5140-5152
Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose: Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design: A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results: Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions: These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- 27 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5140-5152
Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose: Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design: A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results: Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions: These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- 22 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 690-703
Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
Direct measurement of spatial–temporal drug penetration and exposure in the human central nervous system (CNS) and brain tumors is difficult or infeasible. This study aimed to develop an innovative mechanistic modeling platform for quantitative prediction of spatial pharmacokinetics of systemically administered drugs in the human CNS and brain tumors. A nine‐compartment CNS (9‐CNS) physiologically‐based pharmacokinetic model was developed to account for general anatomical structure and pathophysiological heterogeneity of the human CNS and brain tumors. Drug distribution into and within the CNS and tumors is driven by plasma concentration–time profiles and governed by drug properties and CNS pathophysiology. The model was validated by comparisons of model predictions and clinically observed data of six drugs (abemaciclib, ribociclib, pamiparib, olaparib, temuterkib, and ceritinib) in glioblastoma patients. As rigorously validated, the 9‐CNS model allows reliable prediction of spatial pharmacokinetics in different regions of the brain parenchyma (i.e., parenchyma adjacent to CSF and deep parenchyma), tumors (i.e., tumor rim, bulk tumor, and tumor core), and CSF (i.e., ventricular CSF, cranial and spinal subarachnoid CSF). By considering inter‐individual plasma pharmacokinetic variability and CNS/tumor heterogeneity, the model well predicts the inter‐individual variability and spatial heterogeneity of drug exposure in the CNS and tumors as observed for all six drugs in glioblastoma patients. The 9‐CNS model is a first‐of‐its kind, mechanism‐based computational modeling platform that enables early reliable prediction of spatial CNS and tumor pharmacokinetics based on plasma concentration–time profiles. It provides a valuable tool to assist rational drug development and treatment for brain cancer.
- 22 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 690-703
Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
Direct measurement of spatial–temporal drug penetration and exposure in the human central nervous system (CNS) and brain tumors is difficult or infeasible. This study aimed to develop an innovative mechanistic modeling platform for quantitative prediction of spatial pharmacokinetics of systemically administered drugs in the human CNS and brain tumors. A nine‐compartment CNS (9‐CNS) physiologically‐based pharmacokinetic model was developed to account for general anatomical structure and pathophysiological heterogeneity of the human CNS and brain tumors. Drug distribution into and within the CNS and tumors is driven by plasma concentration–time profiles and governed by drug properties and CNS pathophysiology. The model was validated by comparisons of model predictions and clinically observed data of six drugs (abemaciclib, ribociclib, pamiparib, olaparib, temuterkib, and ceritinib) in glioblastoma patients. As rigorously validated, the 9‐CNS model allows reliable prediction of spatial pharmacokinetics in different regions of the brain parenchyma (i.e., parenchyma adjacent to CSF and deep parenchyma), tumors (i.e., tumor rim, bulk tumor, and tumor core), and CSF (i.e., ventricular CSF, cranial and spinal subarachnoid CSF). By considering inter‐individual plasma pharmacokinetic variability and CNS/tumor heterogeneity, the model well predicts the inter‐individual variability and spatial heterogeneity of drug exposure in the CNS and tumors as observed for all six drugs in glioblastoma patients. The 9‐CNS model is a first‐of‐its kind, mechanism‐based computational modeling platform that enables early reliable prediction of spatial CNS and tumor pharmacokinetics based on plasma concentration–time profiles. It provides a valuable tool to assist rational drug development and treatment for brain cancer.
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Supplementary Figure S1. Model-predicted unbound drug – concentration time profiles in the ventricular CSF (Cvcsf), cranial subarachnoid CSF (Cccsf), spinal subarachnoid (Cscsf), adjacent brain tissue (Cbm1), and deep brain parenchyma (Cbm2), following intraventricular injection.
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Supplementary Figure S1. Model-predicted unbound drug – concentration time profiles in the ventricular CSF (Cvcsf), cranial subarachnoid CSF (Cccsf), spinal subarachnoid (Cscsf), adjacent brain tissue (Cbm1), and deep brain parenchyma (Cbm2), following intraventricular injection.
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Supplementary Figure S1. Model-predicted unbound drug – concentration time profiles in the ventricular CSF (Cvcsf), cranial subarachnoid CSF (Cccsf), spinal subarachnoid (Cscsf), adjacent brain tissue (Cbm1), and deep brain parenchyma (Cbm2), following intraventricular injection.
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Supplementary Figure S1. Model-predicted unbound drug – concentration time profiles in the ventricular CSF (Cvcsf), cranial subarachnoid CSF (Cccsf), spinal subarachnoid (Cscsf), adjacent brain tissue (Cbm1), and deep brain parenchyma (Cbm2), following intraventricular injection.